R&D News | pharmaphorum

News

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna

News

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por

News

Roche antibiotic tackles serious drug-resistant pathogen

Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwar

News

Boehringer targets NASH/MASH with $2bn Ribo alliance

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or

News

UK should remove blocks on phage research as AMR fears rise

A new report has called for the UK government to invest in advanced manufacturing plants for bacteriophages – viruses that kill bacteria – that could be an alternative to

News

Anavex hit as Rett syndrome drug flunks test

2024 has started on a low for US biotech Anavex Life Sciences, which saw its shares fall sharply this morning after Rett syndrome candidate Anavex 2-73 failed a clinical trial.

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Novo Nordisk’s Flagship alliance bears obesity, MASH fruit

Roche antibiotic tackles serious drug-resistant pathogen

Boehringer targets NASH/MASH with $2bn Ribo alliance

UK should remove blocks on phage research as AMR fears rise

Anavex hit as Rett syndrome drug flunks test

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks